A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome

Table 4 Hospital indices by treatment group

	Placebo	0.06 mg/kg ALT-836	0.08 mg/kg ALT-836	0.1 mg/kg ALT-836
Days on ventilator	25.5 ± 25.7	14.1 ± 23.1	15.5 ± 10.4	6.4 ± 2.6
Days in ICU	29.2 ± 26.5	15.2 ± 22.1	16.4 ± 10.1	7.1 ± 2.4
Days in hospital	33.3 ± 29.1	29.9 ± 45.6	25.4 ± 12.6	16.7 ± 10.5
ICU free days at SD28^a	8.7 ± 8.1	17.4 ± 9.8	8.4 ± 9.0	20.0 ± 2.4^c
Ventilator free days at SD28^b	11.0 ± 9.8	18.8 ± 10.6	8.4 ± 11.2	21.0 ± 3.1

Values are means ± SD
^a Mean number of days to study day 28 (SD28) that the patients were not admitted to the ICU. Patients that did not survive to SD28 were assigned zero ICU free days
^b Mean number of days to SD28 that the subjects were achieved unassisted breathing. Patients that did not survive to SD28 were assigned zero ventilator free days
^c P < 0.05 compared to placebo group

ISSN: 1471-2466